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Background: There is compelling evidence that psychological factors may have the same or even greater impact
on the possibility of adverse events on cardiac diseases (CD) than other traditional clinical risk factors. Anxiety and
depression are predictors of short- and long-term adverse outcomes, increased risk for higher rates of in-hospital
complications, re-infarction, malignant arrhythmias, and mortality in CD patients. Despite researchers finding that
cognitive behavior therapy (CBT) reduced depressive and anxiety symptoms, the fact that such results are
maintained only in the short term and the lack of maintenance of the long-term affects the absence of changes in
lifestyles, preventing the possibility of a wide generalization of results. Recently wellbeing therapy (WBT) has been
proposed as a useful approach to improve healthy lifestyle behaviors and reduce psychological distress.
Methods/design: The present randomized controlled study will test WBT, in comparison with CBT, as far as the
reduction of symptoms of depression, anxiety and psychological distress, and the improvement of lifestyle
behaviors and quality of life in cardiac patients are concerned. Moreover, innovations in communication
technologies allow patients to be constantly followed in real life. Therefore WBT based on personalized mobile
technology will allow the testing of its effectiveness in comparison with usual WBT.
Discussion: The present study is a large outpatient study on the treatment of co-morbid depression, anxiety, and
psychological distress in cardiac patients. The most important issues of this study are its randomized design, the
focus on promotion of health-related behaviors, and the use of innovative technologies supporting patients’
wellbeing in real life and in a continuous way. First results are expected in 2012.
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Cardiac disease (CD) is the major cause of death world-
wide, accounting for approximately 16.7 million deaths
each year, mainly from heart attack and stroke. Further-
more, such a figure is most likely to increase approxi-
mately to 25 million deaths by 2020, given current
trends. Yet fatalities represent only the tip of the iceberg;
the greater burden of cardiovascular diseases, affecting
an estimated 128 million people, is attributable to non-fatal
cardiovascular events and their long-term consequences.
Although there are well-accepted national guidelines for
both primary and secondary prevention of cardiac illness,
little attention has been devoted to the impact of psycho-
logical risk factors on cardiovascular disease. Nonetheless,
there is wide evidence that psychological risk factors may
cause equal or even more adverse events than other trad-
itional clinical risk factors [1-4].
In patients with ischemic heart disease, anxiety and
depression are predictors of adverse short- and long-
term outcomes [5,6]. Patients suffering from anxiety or
depression during hospital admission are at increased
risk for higher rates of in-hospital complications such as
recurrent ischemia, re-infarction, and malignant arrhyth-
mias [7,8]. They also suffer higher mortality and re-
infarction rates months to years after their initial cardiac
event [8-11].
Affective disorders including clinical depression and
anxiety are common in patients with congestive heart
failure. Prevalence findings show that the prevalence
rates of (all subtypes) anxiety and depression are 18.4%
and 28.6%, respectively [12], and depression is a signifi-
cant predictor of worse evolution for heart failure (HF)
patients [13]. Furthermore, the occurrence of such disor-
ders significantly impacts the quality of life, medical out-
comes, and the use of the healthcare service. A number
of potential mechanisms have been proposed to justify
such an impact, including autonomic nervous system
dysfunction, inflammation, cardiac arrhythmias, and
altered platelet function.
The relationship between emotional distress and the
experience of fatigue in patients with HF may have a
devastating effect on a patient’s ability to cope with and
manage daily activities, including self-care and adher-
ence to recommended treatment. Reports show that
anxiety is associated with mental fatigue, whereas de-
pression is associated with the reduction of activity, low
motivation, and the assumption of lifestyles which are
dysfunctional towards a healthy status. Moreover phys-
ical fatigue is affected by symptomatic distress [14].
In everyday practice it is important to consider that a
high NYHA classification together with emotional pro-
blems may contribute to anxiety or depression, while so-
cial support and active relationships may positively
influence the psychological health of patients with heartfailure [15]. In particular, baseline distress assessed in
primary care (odds ratios (OR) 5.51; 95% confidence
intervals (CI) = 2.56 to 11.62) appears to be an independ-
ent predictor of distress at 9-monthfollow-up. Recent
findings show that anxiety and low social support were
independently associated with HF-related re-admission,
which indicates the need for their inclusion in the
assessment and management of HF [16]. Moreover, data
show that depression ((HR= 1.81) and social isolation
(HR= 2.25) may be mortality predictors independently
of demographics, clinical predictors, and treatment [17].
Failure to understand and address psychological risk
factors for coronary heart disease(CHD) events may be
one reason for which CHD morbidity and mortality
remain so high. Anxiety disorders and depression are
among the most prevalent psychiatric disorders [18].
Given the prevalence of anxiety and depression in the
general population and in patients with CHD, the poten-
tial public health impact for preventing the development
and progression of CHD by properly appreciating the
nature of the link between anxiety or depression and
CHD is enormous [19,20]. Thus, in CVD patients it is
clinically relevant to assess the patient’s psychological
profile and treat his/her emotional conditions causing an
increased risk for major adverse cardiovascular events.
Psychological interventions for anxiety and depression
Major behavioral and drug trials conducted in the last
15 years have focused on the best treatment of depres-
sion in cardiac patients [21]. Cognitive behavioral ther-
apy (CBT) is often successfully used in the treatment of
depressive disorders. Although the adoption of CBT
obtained good results in reducing depression, no benefi-
cial effects for cardiac events in 2 years was reached
inpatients receiving the intervention (24.2%) when com-
pared with a control group undergoing a usual treatment
(24.1%). Because dysfunctional cognition plays a rela-
tively minor role in atypical depression, treatments other
than cognitive-behavioral interventions may be more
beneficial to CHD patients with atypical depression or
exhaustion [22]. Moreover, CBT is a well-documented,
evidence-based treatment appropriate for the treatment
of anxiety, which should be started at the beginning of
cardiac treatment to ensure that patients fully under-
stand their condition [23].
Despite researchers finding that CBT reduces depres-
sive and anxiety symptoms, the limited size of studies
prevents a wide generalization of the results [24].
Recently wellbeing therapy (WBT) has been proposed
as a useful approach to improve healthy lifestyle beha-
viors and reduce psychological distress. WBT aims at en-
hancing psychological wellbeing on the basis of Ryff ’s
[25] six dimensions: autonomy, personal growth, envir-
onmental mastery, purpose in life, positive relations, and
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cacy of this psychotherapy in treating patients with
mood and anxiety disorders, and in preventing relapse
in recurrent depression [26-28]. Moreover, recent results
showed that a sequential combination of CBT and WBT




Starting from current literature, we hypothesize that
WBT and WBT version based on a personalized mobile
technology approach will allow for a reduction of symp-
toms of depression, anxiety, and psychological distress in
cardiac patients. Moreover and therefore, we assume an
improvement in lifestyle behaviors (for example, quitting
smoke, increased physical activity, better medication ad-
herence) and quality of life when compared to CBT and
usual care (UC).
Setting
The study will be conducted in collaboration with the
National Kapodistrian University of Athens, Greece, and
Consorci Sanitari de Terrassa (CST), Spain, during the
3-year EU collaboration project FOR ALL (‘Universal
Service for Managing and Monitoring Cardiac and Psy-
chological Health of European Cardiac Patients’, Project
No. C-029399).
Subjects
Patients with the following eligibility criteria have been
included in the present study: cardiac disease; a current
diagnosis of at least one of the following: major or minor
depression, dysthymia, anxiety according to DSM-IV cri-
teria and HADS criteria, Mini-Mental State Examination
score higher than 24;written informed consent was
requested from the patient. Exclusion criteria included:
uncertain prognosis for 12 months due to other condi-
tions; acute coronary disease in the last 2 months; exist-
ence of another life-threatening illness of the patient
(such as active cancer, chronic kidney failure); severe
neurological problem (brain syndrome/orientation prob-
lem/difficult peripheral neuropathy); severe mental ill-
ness (active psychosis/suicide risk/severe dementia);
linguistic limitations (such as stuttering/untreated audio
impairment); a significant functional problem (such as
unconsciousness/connection to respiration device/con-
finement to a wheelchair or bed/severe walking disabil-
ity/need of help with basic daily activities); objective
limit endangering liability for participation in the seven
meetings (such as remote living location/convict/drug
addiction).
All eligible patients will be approached by trained clin-
ical psychologists during their hospitalization period andwill be screened for depression, anxiety, and psycho-
logical distress (Screening phase). Patients with elevated
scores on such scales will be invited for a baseline inter-
view to further identify possible exclusion criteria. After
this interview, patients satisfying inclusion criteria are
further informed about the design of the study and
asked to give their informed consent (Evaluation phase).
Informed consent will be sought for:(a) using anonym-
ous data from the questionnaires for reports and scien-
tific publications; and (b) for informing the general
practitioner (GP) about the study results. Patients will be
eventually included in the study and randomized
(Randomization phase) to WBT, or WBT-personalized
mobile technology platform (MobWBT), either CBT or
the care as UC. The phases of the recruitment process
are described in Figure 1.
Randomization
Randomization will be performed by statistical experts of
the team study using a computerized random number gen-
erator at http:// www.randomization.com. Randomization
will occur after the baseline measurements and, only in
WBT group, after the first randomization (Figure 1). To
obtain equal numbers in both conditions, a block
randomization design is chosen. After the completion of
the inclusion procedure, the clinical psychologist will
obtain the file containing the condition to which the
patient is allocated.
Design
The comparison among WBT, CBT, and CU will be
assessed in a three-arm randomized controlled clinical
trial. After this first randomization, patients in WBT
group will be randomized across WBT and MobWBT.
Intervention
Wellbeing therapy (WBT) and WBT based on mobile
technology tool (MobWBT)
WBT is based on Ryff ’s cognitive model of psychological
wellbeing [25]. This model was selected on the basis of
its easy applicability to clinical populations [28]. WBT is
divided into three phases (Table 1).
After the first 7 weeks, patients in the WBT arm will be
randomized into two arms: WBT and MobWBT. Patients
in the WBT group will not receive any treatments, while
patients in MobWBT will be followed by a WBT-Mobile
technology tool for 8 weeks (Table 1). Figure 2 shows the
MobWBT technology platform. The MobWBT technol-
ogy platform is based on an elaboration of datasets col-
lected from psychological monitoring in real time and
used to train a machine learning algorithm to recognize
psychological wellbeing conditions. The algorithm is
downloaded onto the smartphone and the training and
testing process will be repeated to improve its predictive
Figure 1 Schematic outline of flow chart of WELL.ME study. During the Screening phase, patients with high anxiety, depression, and
psychological distress will be detected. At Evaluation, inclusion and exclusion criteria will be assessed. After this, the first randomization in three
arms (CBT, WBT, and CU)will be done. After the 7 weeks of treatment, the second randomization will be done in WBT arms, obtaining two sub-
arms: WBT and MobWBT.
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to identify in realtime the psychological wellbeing condi-
tion and deliver personalized WBT techniques precisely at
the moment of greatest need.
Cognitive behavioral therapy (CBT)
CBT techniques for anxiety and depression will be per-
formed [30] using a manual protocol.
CBT-Depression is based on cognitive restructuring and
behavioral techniques. Such techniques towards curing
depression focus on the identification of specific problems
linked to behavior and thinking moods. The therapist uses
structured learning techniquesto teach patients how to
monitor and write down their negative thoughts and men-
tal images. The goal is to recognize how those ideas affect
the patients’ mood, behavior, and physical condition.
Therapists also teach important coping skills, such as
problem solving and planning pleasurable experiences.
CBT-Anxiety addresses negative patterns and distor-
tions in the way we look at the world and at ourselves.
The goal of cognitive behavioral therapy for anxiety is to
identify and correct these negative thoughts and beliefs.
The process involves three steps: Identifying negative
thoughts, challenging negative thoughts, replacing nega-
tive thoughts with realistic thoughts.
Usual care (UC)
In UC no extra intervention is provided. Patients receive
care as defined in the usual management program (sixannual visits with primary care nurse and cardiologist to
monitor disease progression). Patients will be screened
througha set of questionnaires to assess depression and
anxiety every 2 months to record their psychological
symptoms. If scores on these questionnaires indicate a
moderate to severe level, a notification is sent to
theirGP. However, when necessary patients may always
consult their GP and receive treatment for depression/
anxiety by the GP, or (after a referral) by a mental health
specialist.
Treatment procedures
Both WBT and CBT will be conducted for eight 45 min-
utes sessions. The first two sessions will be conducted in
the same week. The remaining six sessions will be con-
ducted over a period of 6 weeks (one session per week).
The total therapy duration for each patient will be 7
weeks. Psychotherapy will be provided by clinical psy-
chologists and psychiatrists trained on specific well-
assessed treatment protocol.
The Medical Ethics Committee of National Kapodis-
trian University of Athens and the Consorci Sanitari de
Terrassa (CST) approved the study protocol and
informed consent. Psychotherapy will be provided indi-
vidually twice a week.
Measurements
Besides the psychological screening baseline at month 1
(T0), all patients will be assessed at months 6 (T1), 12
Table 1 Wellbeing therapy protocol for conventional format (outpatients based tools) and for real-time personalized mobile technologies (Mobile Technology
Tool)
Phases Focus Objectives Outpatient-based tool Mobile technology tool
Initial phase Identifying and setting
episodes of wellbeing into
situational context
Report the circumstances surrounding the
episodes of wellbeing rated on a scale of
0 to 100, with zero being absence of
wellbeing and 100 being the most
intense wellbeing
Diary Mobile diary, personalized by the baseline
assessment results and by an adaptive
learning algorithm depending on patient’s
answers during mobile monitoring
Visual analogical scale for wellbeing
AssessmentMonitor the quality of experience
associated with daily situations
(work, leisure, and so on)
Identification of instances of wellbeing
and of optimal experiences
Intermediatephase Remove the obstacles to
sustained psychological
wellbeing on self-monitoring
of moments and feelings of
wellbeing and graded task
assignments
Identify thoughts and beliefs Graded task assignments of
undertaking particular
pleasurable activities
for a certain time each day
Electronic personalized task assignment
by the baseline assessment results and
by an adaptive learning algorithm
depending on patient’s answers during
mobile monitoring
Leading to premature interruption
of wellbeing
Visual analogical scale for wellbeing
AssessmentIdentify the areas of psychological
wellbeing which are unaffected by
irrational or automatic thoughts and
which are saturated with them
Reinforce and encourage activities that
are likely to elicit wellbeing and
optimal experiences
Final phase Be able to readily identify
moments of wellbeing
Dimensions of psychological wellbeing
are progressively introduced
Graded task assignments of
undertaking particular
pleasurable activities
for a certain time each day
Mobile diary, personalized by the baseline
assessment results and by an adaptive
learning algorithm depending on patient’s
answers during mobile monitoringBe aware of interruptions
to wellbeing feelings (cognitions)
Guide the patient from an impaired
level to an optimal level according
to the above six dimensions
Electronic personalized task assignment
by the baseline assessment results and
by an adaptive learning algorithm
depending on patient’s answers during
mobile monitoring
Follow optimal experiences
Meeting the challenge that
may entail optimal
experiences is emphasized

















Figure 2 Wellbeing therapy based on real-time personalized mobile technologies.
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view of variables measured at each time point. Moreover,
at the baseline assessment, questions on demographic
variables (for example, age, marital status, work, educa-
tional level, socioeconomic status), psychiatric history
(for example, previous diagnosis of depression and/or
anxiety, family history regarding psychiatric diagnosis),
and/or health behaviors (for example, alcohol use, smok-
ing habits, physical activity) will be included. Clinical
variables and diagnosis of other chronic diseases will be
obtained from medical records.
Primary outcome measures
Healthy lifestyle
Diet, physical activity, weight, blood lipids, glucose, and
insulin were measured at baseline and at months 6, 12,
and 24.
Depression and anxiety
The Patient Health Questionnaire-9 (PHQ-9) is a short
self-report questionnaire based on the nine symptoms of
major depression, as defined in the Diagnostic and Stat-
istical Manual (DSM-IV). The scale has a good overall
accuracy, sensitivity, and specificity in a general primaryTable 2 Variables measured at each time point
PHQ-9 GAD-7 DCPR PSI SF-12 PGWBI LHFQ
T0 X X X X X X X
T1 X X X X
T2 X X X X X X X
T3 X X X X X X Xcare population [31]. A cutoff of 7can be used to indi-
cate possible depression [32].
The Generalized Anxiety Disorder-7 scale (GAD-7)has
shown good reliability and validity to detect generalized
anxiety disorder as well as other anxiety disorders in pri-
mary care patients [33]. A score >7can be used to indi-
cate a possible anxiety disorder.
The Diagnostic Criteria for Psychosomatic Research
(DCPR) [34] represents a diagnostic and conceptual
framework that aims at translating psychosocial variables
derived from psychosomatic research into operational
tools. A set of 12syndromes was developed: disease pho-
bia, thanatophobia, health anxiety, illness denial, persistent
somatization, functional somatic symptoms after a psychi-
atric disorder, conversion symptoms, anniversary reaction,
irritable mood, type A behavior, demoralization, and
alexithymia.
The Psychosocial Index (PSI) [35] is a simple self-
rated instrument including 55 items for assessing stress,
psychological distress, abnormal illness behavior, and
wellbeing.
Psychological Wellbeing Scale (PWB) [25] is used in
the original 20-item per scale version devised to evaluate
six dimensions of well-being: (1) autonomy; (2) environ-
mental mastery; (3) personal growth; (4) positive rela-
tionships with others; (5) purpose in life; and (6) self-
acceptance.
Quality of life/Health status
Health Survey (SF-12) is a health status questionnaire
composed by two components (mental and physical)
measuring functional status, wellbeing, and general
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The scale was developed to be used in a variety of
chronic diseases [37].
The Psychological General Wellbeing Index (PGWBI)
is an index to measure the level of subjective psycho-
logical wellbeing that has been validated by decades of
clinical practice. PGWBI has been developed as a tool to
measure self-representations of intra-personal affective
or emotional states reflecting a sense of subjective well-
being or distress, thus capturing what we could call a
subjective perception of wellbeing [38,39]. The original
PGWBI consists of 22 self-administered items, rated on
a six-point scale, which assess psychological and general
wellbeing of respondents in six health-related quality of
life (HRQoL) domains: anxiety; depressed mood; positive
wellbeing; self-control; general health; and vitality. Each
item may score 0 to 5, referring to the last 4weeks of the
subject’s lifetime. Each domain is defined by a minimum
of three to a maximum of five items. The scores for all
domains can be summarized into a global summary
score, which reaches a theoretical maximum of 110
points, representing the best achievable level of well-
being [38], a sort of ‘state of bliss’. A number of studies
are cross-sectional and longitudinal psychometric valid-
ation and correlation with a large number of other in-
dexes of medical and mental health, through different
contexts (communities, institutions, hospitals) [40]. The
average PGWB total score of results from studies of the
population is between 80 and 81 points.
Minnesota Living With Heart Failure Questionnaire
(LHFQ) [41] measures patients’ perception of the effects
of HF in their lives. It is a questionnaire initially pre-
pared to be self-administered, formed by 21 items that
contemplate the physical, socioeconomic, and psycho-
logical limitations frequently reported by patients con-
nected with their HF. Patients’ self- assessment is
quantified by the sum of answers of the 21 items. The
scale of answers for each question ranges from 0(‘no’) to
5(‘too many’), where0represents ‘no limitations’ and 5
represents ‘maximum limitation’. Higher scores indicate
worse HRQOL.
Ethical principles
The study of this protocol does not involve the adminis-
tration of drugs. However, the investigator is responsible
for ensuring that the study is conducted in accordance
with the principles defined by the 18th World Medical
Assembly (Helsinki, 1964) and subsequent amendments
established by the 29th (Tokyo, 1975), 35th (Venice,
1983), 41st (Hong Kong, 1989), and the 48th World
Medical Assembly (Somerset West, South Africa, 1996),
and 52nd (Edinburgh, Scotland, 2000) General Assem-
bly. The study will also be conducted in accordance to
the Ministerial Decree of 15 July 1997 transposing thetext of the rules of Good Clinical Practice for human
trials of medical products within the EEC.
Planned statistical analyses
The demographic and clinical characteristics of the two
study groups will be compared at baseline to verify their
homogeneity. To do this analysis of variance (ANOVA)
for continuous variables and chi-square test of Mantel-
Haenszel test for discrete variables will be used.
Completer and intent-to-treat analysis will be accom-
plished to compare treatments both in primary and sec-
ondary outcomes. First prevalence of depression,
anxiety, and psychological distress will be displayed in
frequency tables and both conditions (control and inter-
vention) will be compared using the chi-square (Fisher’s
exact test when appropriate) and Student’s t-test, for
discrete and continues variables respectively. The effect
of the intervention will be determined using multilevel
analyses (mixed effect regression models) to compare
baseline and follow-up measures of all continuous data.
In all these analyses a P value of <0.05 will be considered
statistically significant.
Sample size calculation
In this study the change in scores inPHQ-9 and GAD-7
are chosen as primary outcome measures to determine
the effect of a disease management approach. A differ-
ence of 0.5 standard deviations is considered necessary
to find a clinically significant effect of the intervention.
In order to detect this difference and assuming a 80%
power, a minimum of 80 patients is needed in each con-
dition [42]. When assuming that 20% of participants
dropout, quite a normal figure in this type of research, a
minimum of 80 patients per condition is needed to
maintain sufficient power. We expect that in order to
reach such a number, anticipating a response rate of 70%
of which 20% is eligible, a total of 600 patients will have
to be screened.
Discussion
This article describes the background, objectives, and
design of a large randomized controlled trial that will
test the effectiveness of WBT to treat depression, anx-
iety, psychological distress, and to improve healthy life-
style in cardiac disease patients in comparison with CBT
and CU. Moreover, the research protocol will test the ef-
fectiveness of MobWBT in comparison with WBT. Pre-
vious research on cardiac patients has already shown
that depression and anxiety are common co-morbidities
in these patient populations, and are negatively asso-
ciated with healthy lifestyle and health status, and posi-
tively with morbidity, mortality, and healthcare costs
[8-11,17,18]. However, randomized studies on the effects
of treating depression, anxiety, and psychological distress
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of results [24]. Recently WBT has been proposed as a
useful approach to improve healthy lifestyle behaviors
and reduce psychological distress. Therefore, this study
was developed to test the effectiveness of a WBT ap-
proach for co-morbid depression and anxiety in these
patient populations. Moreover, innovations in communi-
cation technologies allow patients to be followed con-
tinuously in real life. Therefore, through WBT based on
personalized mobile technology it will be possible to test
the effectiveness of these technologies in comparison
with usual WBT.
Conclusions
In conclusion, both depression and anxiety are common
diseases in cardiac patients that may provoke a consider-
able worsening of the cardiac pathology condition.
However, research of possible treatment strategies to
alleviate this additional burden is limited. Therefore,
the WELL.ME study tests the use of WBT to treat
co-morbid depression and anxiety in patients with cardiac
disease.
Trial status
The WELL.ME study trial was conceived and designed
in 2007. At the time this manuscript was submitted full
approval by the Medical Ethics Committee had been
obtained.
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